Ger­man court de­nies va­lid­i­ty of Cure­Vac patent claim in fight with BioN­Tech over Covid-19 vac­cine 

A Ger­man court on Tues­day in­val­i­dat­ed a Cure­Vac patent that was part of the biotech’s on­go­ing fight with BioN­Tech over the mR­NA tech­nol­o­gy used in Covid-19 vac­cines.

Had Cure­Vac’s claims been up­held, the biotech could have been in a po­si­tion to re­ceive a frac­tion of BioN­Tech’s Covid-19 vac­cine rev­enues. In­stead, Tues­day’s an­nounce­ment about the Ger­man Fed­er­al Patent Court’s de­ci­sion sent Cure­Vac’s shares $CVAC down 25%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER